AMRX Q3 2023 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$620M+13.7% YoY

Gross Profit

$233M37.5% margin

Operating Income

$76M12.2% margin

Net Income

$10M1.6% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

+3.5%

Cash Flow

Operating Cash Flow

$81M

Free Cash Flow

$68M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$3.7B

Total Liabilities

$3.5B

Stockholders' Equity

$331M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$620M	$546M	+13.7%
Gross Profit	$233M	$194M	+19.7%
Operating Income	$76M	$44M	+70.6%
Net Income	$10M	-$3M	+460.1%

Revenue Segments

Generics Segment

$391M63%

Av K A R E Segment

$132M21%

Amneal Specialty Pharma Segment

$97M16%